Bayer G4A, formerly known as Grants4Apps, launched in Berlin in 2013, originally with the aim of funding healthcare mobile apps. As the digital health landscape progressed over the years, so did they. G4A is now a global team that develops and scales solutions anchored in behavioral science.

Bayer G4A

HealthTech Arkansas is an investment firm that targets three areas of healthcare innovation digital health, medical devices, and diagnostic platforms. The firm seeks technologies that can improve our providers’ operations by improving the quality of care, enhancing efficiencies, and reducing costs.

HealthTech Arkansas

KHP Ventures is an investment firm that provides innovative ideas for healthcare.

KHP Ventures

Golden Angels Investors is an angel investment group making investments in entrepreneurial ventures. The firm's members bring a track record of business success and a deep commitment to assisting entrepreneurs in building great companies. It leads opportunities directly as well as participates in opportunities led by other investors. Golden Angels Investors was established in 2002 and is headquartered in Brookfield, Wisconsin.

Golden Angels Investors

We have invented the most innovative financial products that are intended to restore investors' faith in Alternative Investments through a contra-market strategy and solid investment thesis meant to ''de-risk'' the non-correlated private markets. We specialize in true Capital Partnerships with Entrepreneurs in need of Venture Capital that reinforces above-market, risk-adjusted returns, to our Investors, through ''Tri-Party Venture Funds®'' , ''Private BDCs'' and ''Specialty Hedge Funds'' as our leading Alternative Investments that serve them.

Capital Q® Ventures Inc.

Angel Syndicate investing in health tech out of Berlin

Springboard Health Angels

Solardis Health Ventures is an investment firm.

Solardis Health Ventures

They invest in disruptive companies with potential to dominate global markets. They look for companies and entrepreneurs with fundamentally strong business model. They take the time and effort to understand each idea and decide on its merits and potential through Their comprehensive evaluation process.

CerraCap Ventures

Carma Fund is an early-stage investment fund for advancing life science and healthcare technologies.

Carma Fund

Acorai

Acorai is building a non-invasive heart failure monitoring platform with direct intracardiac pressure monitoring (ICPM) at its core. Acorai offers accurate and cost-efficient heart failure care using patented technology that leverages a novel combination of sensor technologies and machine learning to enable non-invasive ICPM, the only proven way to improve outcomes in HF patients. The device has been clinically validated, designated FDA Breakthrough Device, and will enter the market in 2025. The company's product can non-invasively monitor cardiac and pulmonary pressure by utilizing machine-learning techniques to analyze pressure dynamics in acoustic, vibratory, and waveform data.

Acorai is a Swedish medical device startup developing a first-of-its-kind, scalable device for non-invasive intracardiac pressure monitoring to improve heart failure management for over 64 million patients worldwide. The company's heart monitor uses a patented SAVE Sensor System that integrates seismic, acoustic, visual, and electrical sensors to collect data, which is then analyzed by proprietary machine learning models to estimate diastolic, systolic, and mean pulmonary artery pressures.

Acorai wins €2.3m grant to help fund trial for heart monitoring device

up, Acorai, embarks on the next vital stage towards regulatory approval

up, Acorai, secures €2.3m grant funding from the European Commission

Acorai raises $4.5m to advance heart monitoring device trial

Heart failure monitoring startup Acorai turns heads with oversubscribed seed

Acorai’s Study of Noninvasive Pressure Monitoring Device in Heart Failure Begins Enrollment

Swedish heart failure startup Acorai closes €4.1 million to change the paradigm on acute care settings

Swedish Acorai secures $4.5M in seed funding for its heart monitoring device

Swedish Acorai, pioneering heart failure solution, receives €2.3M grant funding from European Commission

Pushing the envelope in MedTech with emerging technologies

Next-gen Medical Devices

Acorai from Sweden raises €4.2M to advance Non-Invasive Cardiac Monitoring Devices

Acorai is a Swedish medical device startup developing a first-of-its-kind, scalable device for non-invasive intracardiac pressure monitoring to improve heart failure management for over 64 million patients worldwide. The company's heart monitor uses a patented SAVE Sensor System that integrates seismic, acoustic, visual, and electrical sensors to collect data, which is then analyzed by proprietary machine learning models to estimate diastolic, systolic, and mean pulmonary artery pressures.Acorai's heart monitor has demonstrated accuracies comparable to invasive gold-standard measurements in a 400-patient feasibility study conducted in June 2023. The non-invasive, handheld device allows healthcare professionals to quickly obtain intracardiac pressure readings by simply holding it against the patient's chest, without requiring specialized training or dedicated equipment.In August 2023, the company received Breakthrough Device designation from the US Food and Drug Administration (FDA) for its heart monitor. Acorai aims to submit the device for FDA clearance and CE-marking in 2024, with full commercial launch expected in 2025. The company has initiated the CAPTURE-HF global clinical trial across 11 sites in several countries to validate the device's performance on 1,200 patients undergoing catheterization procedures.&nbsp;

Convergent Dental, Inc. is a privately owned dental equipment and technology company. Its flagship product, Solea, is the only CO2 laser cleared by the FDA for all-tissue indications, delivering an anesthesia-free, blood-free, and suture-free experience for dentists and patients. Solea represents a breakthrough in dental laser technology, offering a distinct experience compared to traditional instruments or earlier laser treatments.
Solea is a novel 9.3-micron CO2 laser that nears the peak absorption of hydroxyapatite (enamel), enabling it to vaporize enamel with speed and precision. This unique wavelength, coupled with computer-controlled motors (galvos) that manipulate the beam thousands of times per second, allows dentists to perform procedures ranging from hard tissue to soft tissue with total control and efficiency.
A key feature of Solea is its variable-speed foot pedal, which lets dentists seamlessly transition from hard to soft tissue by adjusting the pressure applied. This intuitive design streamlines the learning curve for dentists accustomed to using a drill. Solea's three ergonomic handpieces – Contra-Angle, Straight, and Ultraguide – further enhance its versatility across various procedures.
Solea not only improves patient experiences but also offers practice benefits such as increased productivity, new patient flow, and efficiency gains. In October 2022, Convergent Dental received FDA clearance for Solea to aid in reducing mineral loss in dental enamel, protecting teeth against acid attack and caries development. This breakthrough application was commercially launched in November 2023 under the name Solea Protect.

Convergent Dental

Ossio is an orthopedic fixation technology company that has developed OSSIOfiber Intelligent Bone Regeneration Technology, a breakthrough implant material designed to securely fixate and fully integrate into the body's native anatomy without leaving any permanent hardware behind. This technology addresses the limitations of conventional metal and resorbable implants, combining unparalleled mechanical strength with natural bone healing.
Made from a proprietary mineral fiber matrix held together by a naturally degradable polymer, OSSIOfiber implants provide surgeons with a more biologically friendly way to restore patient stability and mobility. These implants are engineered to provide the strength required for functional fixation while allowing full integration into the native bone without adverse biological response.
Ossio's product portfolio includes compression screws, trimmable fixation nails, hammertoe fixation systems, suture anchors, and compression staples, all made with OSSIOfiber technology. These implants have received multiple FDA clearances since 2019, and the company has initiated commercialization of its products in the US. As of March 2022, over 6,000 implantations of OSSIOfiber products had been performed, demonstrating adoption of this innovative technology.
OSSIOfiber Intelligent Bone Regeneration Technology can address various surgical applications through the manufacturing of implant designs like nails, screws, staples, anchors, and plates. Ossio plans to pursue multiple applications in distal extremities, trauma, sports, reconstruction, pediatrics, and spine segments.
In February 2023, Ossio launched the world's first and only non-permanent compression staple made with OSSIOfiber technology, designed for predictable bone in-growth, regeneration, and replacement.

Ossio

Casana is a healthcare technology company that has developed the Heart Seat, an innovative toilet seat that enables effortless, integrated, and consistent in-home health monitoring. The Heart Seat is a replacement for a standard toilet seat and is designed to measure key clinical parameters such as heart rate, blood oxygen saturation (SpO2), and blood pressure.
In May 2023, Casana received FDA clearance for the Heart Seat to measure heart rate and SpO2 in adults aged 22 years and older, weighing between 90 to 350 pounds. The company plans to file for additional indications, including systolic and diastolic blood pressure, with the goal of launching the product in the market by the end of 2023.
The Heart Seat is equipped with sensors that passively capture health data whenever the seat is used, eliminating the need for user compliance or behavior changes. The data is automatically uploaded to the Casana Cloud, where it can be viewed by healthcare providers, enabling them to monitor patients' health trends and respond to changes in near real-time.
Casana's technology allows for the effortless collection of consistent and reliable data, assisting medical teams in monitoring chronic conditions beyond the hospital or physician's office. The company aims to unlock a new category in healthcare technologies that enables seamless, integrated, and continuous in-home health monitoring.
In January 2022, Casana was acquired by an undisclosed entity, further accelerating the commercialization of the Heart Seat.

Casana

Neurent Medical is a company pioneering innovative non-surgical interventions to treat chronic inflammatory sinonasal diseases, particularly chronic rhinitis. The company's flagship product is the NEUROMARK System, a device that received US Food and Drug Administration (FDA) 510(k) clearance in October 2021.
The NEUROMARK System is designed to gently apply controlled low-power radio frequency (RF) energy to target regions of the nasal cavity, disrupting the parasympathetic nerve signals that can trigger an inflammatory response. This alleviates chronic rhinitis symptoms such as persistent congestion, rhinorrhea (runny nose), swelling of the mucosal membrane, sneezing, and nasal itching. The system's unique flexible leaflet design and proprietary smart algorithms enable precise neurolysis (disruption) of the posterior nasal nerves (PNN) and accessory pathways, accommodating a range of patient anatomies while maintaining mucosal and vascular integrity.
Neurent Medical announced the limited market release of the NEUROMARK System in the US in February 2023, following the establishment of a new Category I Current Procedural Terminology (CPT) code by the American Medical Association (AMA) for PNN procedures, effective January 2024. The American Academy of Otolaryngology-Head and Neck Surgery (AAO-HNS) also endorsed the PNN procedure in 2023.

Neurent Medical

Genetesis is a medical imaging company specializing in biomagnetic cardiac imaging solutions. It has developed CardioFlux, a flagship magnetocardiography (MCG) system that non-invasively identifies myocardial ischemia, a condition where blood flow to the heart muscle is reduced. The technology measures the magnetic fields generated by the heart's electrical activity to detect ischemia within minutes, without using pharmaceuticals or radiation. CardioFlux MCG is designed to provide advanced imaging while prioritizing patient comfort.
The company's solutions target the diagnosis of coronary microvascular disease (CMD), a condition that has been challenging to identify due to a lack of effective functional diagnostics. By offering an accurate and rapid test for CMD, Genetesis aims to address an unmet clinical need and enable timely management of the condition.
In April 2023, the US Food and Drug Administration (FDA) granted CardioFlux MCG Breakthrough Device designation for the non-invasive diagnosis of myocardial ischemia in patients suspected of having CMD.
Genetesis was founded in 2013 and is headquartered in Mason, Ohio. The company has received over USD 40 million in funding to date, including a USD 17.5 million Series C round in October 2022. In April 2020, TDK Ventures, the corporate venture capital arm of TDK Corporation, invested in Genetesis, providing access to TDK's expertise in areas like biomagnetic sensors and magnetic noise suppression.

Genetesis

Companies that develop diagnostic devices used in a hospital setting to identify a disease, condition, or injury, such as imaging systems and endoscopes

Companies that develop implantable medical devices designed to be surgically placed inside the human body, either temporarily or permanently, including devices such as pacemakers, artificial joints, stents, and cochlear implants

Companies that develop non-surgical devices that are used in a procedure or intervention to cure or relieve a patient from an illness or disease such as laser treatments, dental equipment, and wound care management

Companies that develop monitoring devices that are used in a hospital setting to measure patient vital signs and ensure patient well-being post-treatment, such as cardiac and respiratory monitoring systems

Providers of software that enhances the functionality of medical device hardware (diagnosis, treatment, and monitoring)

Companies that develop surgical devices involving invasive interventions (cutting into a patient's body tissues) to treat, cure, or relieve a patient of an illness or disease

Companies that develop devices to administer pharmaceutical substances into a patient's body, ensuring controlled release or targeted delivery, specifically for use in clinical settings to treat or manage medical conditions effectively

Providers of software that helps manage risks, ensure quality, and streamline audit processes during medical device development

IoT connects devices to EHR systems for precise patient diagnosis and treatment support

Devices are linked to software platforms that use digital technologies such as AI/ML and VR

Startups leverage AI/ML and deep learning to support patient diagnosis and early detection

<div>
 Acorai, a company that manufactures heart failure management devices, has successfully raised EUR 4.2 million (USD 4.4 million) in investment from the European Innovation Council (EIC) Fund, Taiwan Medical University, and private investors. This funding round comes after the company had an oversubscribed seed equity round earlier in January 2024, where it managed to raise USD 4.5 million.
 The recent funding will help Acorai to finalize clinical trials, obtain necessary regulatory approvals in the US and Europe, and prepare for a planned product launch in the market by the year 2026. For future equity financing in 2025, the company has set aside an additional EUR 6 million (USD 6.3 million) from the EIC Fund.
</div>

Acorai

Sources

About EDGE

Contact Us

Resources

Area of Focus

Technology Research Made Effortless